- Organizations: Kala Pharmaceuticals
Pipeline
Favorable preliminary data reported for KIO-301 in RP treatment
Kiora Pharmaceuticals' first-in-human ABACUS study suggests promising vision function restoration.
Pipeline
FDA grants Fast Track designation to KPI-012 for PCED
Kala Pharmaceuticals’ lead product candidate is a human MSC-S therapy.
Pipeline
FDA accepts Kala Pharmaceuticals’ IND application for PCED treatment
The company plans on initiating enrollment for a phase 2b trial this quarter.
Archives